Results 211 to 220 of about 89,305 (304)

Paroxysmal Nocturnal Haemoglobinuria‐Associated Acute Cutaneous Thrombosis and Haemolysis in the Setting of Parvovirus B19 and Varicella Zoster Virus Infection

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT A 28‐year‐old male with paroxysmal nocturnal haemoglobinuria (PNH) presented with headache, nasal bridge discomfort and haemoglobinuria. He developed a macular‐papular rash which rapidly progressed into purpura, necrosis and peri‐orbital oedema. Investigations demonstrated severe haemolytic anaemia and acute parvovirus B19 infection.
Louise J. Potter, Roochi Trikha, Shreyans Gandhi, Joanne Large, Tanya N. Basu, Jeanne Boissiere, Hannah Devine, Taku Sugai, Aushna Rasool, Austin Kulasekararaj   +9 more
wiley   +1 more source

Novel immunotherapeutic strategies for diffuse large B-cell lymphoma: a comprehensive review. [PDF]

Front Immunol
Li Y, Zhang Y, Zhu C, Han Y, Gao X, Yue J, Wang Y.   +6 more
europepmc   +1 more source

A Real‐World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma in the United States

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Tafasitamab, a CD19‐targeting immunotherapy, is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) ineligible for autologous stem cell transplant.
Kim Saverno, Loretta J. Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Parisa Asgarisabet, Narendranath Epperla   +8 more
wiley   +1 more source

A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer. [PDF]

J Transl Med
Xu F, Liu W, Su L, Yang L, Zhang Y, Liu B, Liu S, Liu Z, Chen Z, Lu Y, Zhang N, Huang R, Zhao H, Song W.   +13 more
europepmc   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. [PDF]

Cells
Yasui H, Idogawa M, Ishida T, Imai K.
europepmc   +1 more source

Nanobody‐Mediated c‐MYC Degradation Inhibits Tumor Cell Progression

MedComm, Volume 7, Issue 4, April 2026.
A cell‐permeable nanobody strategy was developed to target the intrinsically disordered oncoprotein c‐MYC. A synthetic nanobody, M4, binds the central PEST region of c‐MYC (241–263) and promotes c‐MYC degradation by enhancing Thr58 phosphorylation. Conjugation of M4 to a cell‐penetrating peptide (CPP) generates CPM4, which efficiently accumulates in ...
Yuanyuan Xue, Hao Jiang, Zhaoyun Zong, Xiaolin Tian, Zelong Miao, Ting Li, Yali Wei, Haiteng Deng   +7 more
wiley   +1 more source

Development of a humanized anti-fibrin monoclonal antibody for the treatment of neuroinflammatory and retinal diseases. [PDF]

J Neuroinflammation
Kantor AB, Rickert M, Cheng H, Flanagan K, Salgotra V, Suppahia A, Ryu JK, Widboom PF, Warfield JR, Akassoglou K, Stavenhagen JB.   +10 more
europepmc   +1 more source

Non‐Viral Cytokine‐Inducible SH2 Containing Protein Locus‐Specific Integrated Fibroblast Activation Protein Alpha‐Targeting Chimeric Antigen Receptor T Cells Achieve Potent Antitumor Efficacy in Glioblastoma

MedComm, Volume 7, Issue 4, April 2026.
FAPα is a dual target on glioblastoma cells and perivascular cells. Using a high‐affinity anti‐FAPα nanobody, we generated CISH‐KO FAPα‐CAR‐T cells via non‐viral CRISPR–Cas9 integration. These cells demonstrated enhanced proliferation and superior antitumor efficacy in patient‐derived organoids and orthotopic mouse models compared to conventional CAR‐T
Xin Dong, Yao Sun, Yuetong Guo, Jiao Wang, Fei Wang, Ziming Wang, Ruizhen Li, Fei Xie, Tingting Tan, Baijie Cheng, Ronghan Huang, Shu Zhang, Xiaotong Lin, Zhaoze Guo, Hubing Wu, Hao Wu, Xubiao Zhang, Guozhu Xie   +17 more
wiley   +1 more source